1. Home
  2. IFRX vs MVO Comparison

IFRX vs MVO Comparison

Compare IFRX & MVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • MVO
  • Stock Information
  • Founded
  • IFRX 2007
  • MVO 2006
  • Country
  • IFRX Germany
  • MVO United States
  • Employees
  • IFRX N/A
  • MVO N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • MVO Oil & Gas Production
  • Sector
  • IFRX Health Care
  • MVO Energy
  • Exchange
  • IFRX Nasdaq
  • MVO Nasdaq
  • Market Cap
  • IFRX 56.4M
  • MVO 66.6M
  • IPO Year
  • IFRX 2017
  • MVO N/A
  • Fundamental
  • Price
  • IFRX $0.79
  • MVO $5.72
  • Analyst Decision
  • IFRX Strong Buy
  • MVO
  • Analyst Count
  • IFRX 4
  • MVO 0
  • Target Price
  • IFRX $7.75
  • MVO N/A
  • AVG Volume (30 Days)
  • IFRX 282.5K
  • MVO 55.1K
  • Earning Date
  • IFRX 08-07-2025
  • MVO 01-01-0001
  • Dividend Yield
  • IFRX N/A
  • MVO 17.46%
  • EPS Growth
  • IFRX N/A
  • MVO N/A
  • EPS
  • IFRX N/A
  • MVO 1.46
  • Revenue
  • IFRX $140,242.00
  • MVO N/A
  • Revenue This Year
  • IFRX N/A
  • MVO N/A
  • Revenue Next Year
  • IFRX $6,309.47
  • MVO N/A
  • P/E Ratio
  • IFRX N/A
  • MVO $7.29
  • Revenue Growth
  • IFRX 30.90
  • MVO N/A
  • 52 Week Low
  • IFRX $0.71
  • MVO $8.85
  • 52 Week High
  • IFRX $2.82
  • MVO $13.95
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 37.43
  • MVO 46.88
  • Support Level
  • IFRX $0.78
  • MVO $5.65
  • Resistance Level
  • IFRX $0.83
  • MVO $5.94
  • Average True Range (ATR)
  • IFRX 0.04
  • MVO 0.23
  • MACD
  • IFRX 0.03
  • MVO -0.01
  • Stochastic Oscillator
  • IFRX 52.00
  • MVO 23.94

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About MVO MV Oil Trust Units of Beneficial Interests

MV Oil Trust is a statutory trust. Its underlying properties consist of MV Partners, LLC's (MV Partners) net interests in all of its oil and natural gas properties, which are located in the Mid-Continent region in the States of Kansas and Colorado. These properties include producing oil and gas wells.

Share on Social Networks: